<DOC>
	<DOCNO>NCT01693068</DOCNO>
	<brief_summary>This Phase 2 , multicenter , randomize , control , open-label trial pimasertib versus dacarbazine aim confirm activity pimasertib previously untreated subject N-Ras mutate locally advanced metastatic malignant cutaneous melanoma compare progression-free survival ( PFS ) subject treat either pimasertib dacarbazine get well understanding efficacy , safety , pharmacogenomics ( PGx ) relationship pimasertib exposure .</brief_summary>
	<brief_title>Phase II Trial Pimasertib Versus Dacarbazine N-Ras Mutated Cutaneous Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Subjects measurable , histologically cytologically confirm , locally advanced metastatic cutaneous melanoma ( stage III c M1ac ) NRas mutate . If NRas mutational status unknown screening , must prospectively defined inclusion . If NRas mutational status already know screening , must retrospectively confirm inclusion sponsor . 2 . Tumor lesion amenable biopsy available tumor tissue archival sample . 3 . Age ≥ 18 year . 4 . Has read understood inform consent form willing able give inform consent . Fully understand requirement trial willing comply trial visit assessment . 5 . Women childbearing potential must negative blood pregnancy test screen visit . For purpose trial , woman childbearing potential define : `` All female subject puberty unless postmenopausal least two year , surgically sterile '' . 6 . Female subject childbearing potential male subject female partner childbearing potential must willing avoid pregnancy use adequate method contraception 2 week prior , four week last dose trial medication . Effective contraception define method contraception failure rate le 1 % per year . Adequate contraception define follow : two barrier method one barrier method spermicidal intrauterine device oral contraception female partner male subject . 1 . Has previous systemic treatment locally advance metastatic cutaneous melanoma ( exclude adjuvant treatment ) . 2 . Has nonmeasurable lesion , disease evaluable RECIST v. 1.1 3 . Has Eastern Cooperative Oncology Group performance status ( ECOG PS ) &gt; 1 . 4 . Has bone marrow impairment evidence Hemoglobin &lt; 10.0 g/dL , Neutrophil count &lt; 1.5 x 10^9/L , platelet &lt; 100 x 10^9/L . 5 . Has renal impairment evidence calculated creatinine clearance &lt; 60 mL/min ( accord CockcroftGault formula ) . 6 . Has liver function abnormality define total bilirubin &gt; 1.5 x ULN , AST/ALT &gt; 2.5 x ULN , subject liver involvement AST/ALT &gt; 5 x ULN . 7 . Has significant cardiac conduction abnormality , include QTc prolongation &gt; 480 m and/or pacemaker clinically relevant impair cardiovascular function . 8 . Has hypertension uncontrolled medication 9 . Has retinal degenerative disease ( hereditary retinal degeneration agerelated macular degeneration ) , history uveitis , history retinal vein occlusion ( RVO ) eye condition would consider risk factor RVO ( e.g. , uncontrolled glaucoma ocular hypertension ) . 10 . Has know active CNS metastases unless previously radiotherapy treat , stable CT scan least 3 month without evidence cerebral edema requirement corticosteroids anticonvulsant . 11 . History difficulty swallowing , malabsorption chronic gastrointestinal disease , condition may hamper compliance and/or absorption test product . 12 . Known HIV positivity , active hepatitis C , active hepatitis B . 13 . Has undergone surgical intervention within 28 day Day 1 trial drug treatment . 14 . Has receive extensive prior radiotherapy 30 % bone marrow reserve , prior bone marrow/stem cell transplantation within 5 year Day 1 trial drug treatment . 15 . Has history significant medical disease major gastric small bowel surgery , recent drainage significant volume ascites pleural effusion psychiatric condition might impair subject wellbeing preclude full participation trial . 16 . Has know hypersensitivity dacarbazine . 17 . Is pregnant nurse female . 18 . Participated another clinical trial within past 28 day . 19 . Has CPK level baseline NCI CTCAE Grade ≥ 2 ( i.e &gt; 2.5 x ULN ) , and/or previous history myositis rhabdomyolysis . 20 . Is suitable treatment approve BRaf inhibitor ( exclusion criterion implemented German amendment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cutaneous Melanoma</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>Pimasertib</keyword>
	<keyword>N-Ras</keyword>
</DOC>